Jasper Therapeutics
JSPR
59 hedge funds and large institutions have $380M invested in Jasper Therapeutics in 2024 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 19 increasing their positions, 6 reducing their positions, and 14 closing their positions.
885% more capital inflows, than outflows
Capital inflows: $101M | Capital outflows: $10.3M
399% more call options, than puts
Call options by funds: $4.27M | Put options by funds: $855K
217% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 6
200% more funds holding in top 10
Funds holding in top 10: 2 → 6 (+4)
136% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 14
48% more funds holding
Funds holding: 40 → 59 (+19)
13.1% more ownership
Funds ownership: 73.41% → 86.51% (+13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Avidity Partners Management
Dallas,
Texas
|
+$13.5M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$12.8M |
| 3 |
Samsara BioCapital
Palo Alto,
California
|
+$9.33M |
| 4 |
Great Point Partners
Greenwich,
Connecticut
|
+$7.24M |
| 5 |
Rock Springs Capital Management
Baltimore,
Maryland
|
+$7.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.69M |
| 2 |
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.76M |
| 3 |
Ally Bridge Group
New York
|
-$1.35M |
| 4 |
Landscape Capital Management
Englewood,
New Jersey
|
-$1.2M |
| 5 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
-$1.09M |
JSPR Hedge Fund Activity: Q1 2024 in Review
59 of the 6,969 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q1 2024, worth a combined $380M — up 493% from $64.1M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new JSPR positions and 14 closed out — a net gain of 19 holders — while 19 added to existing stakes and 6 trimmed.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $13.5M. The largest seller was Sphera Funds Management, cutting an estimated $3.69M.
- 59 institutional investors held Jasper Therapeutics (JSPR) as of Q1 2024, up from 40 in Q4 2023.
- Funds reported $380M of Jasper Therapeutics stock for Q1 2024, up 493% quarter-over-quarter.
- 33 funds opened new Jasper Therapeutics positions in Q1 2024 and 14 closed out, a net change of +19 holders.
- The largest Jasper Therapeutics buyer in Q1 2024 was Avidity Partners Management, an estimated $13.5M added.
- The largest Jasper Therapeutics seller in Q1 2024 was Sphera Funds Management, an estimated $3.69M sold.
Based on aggregated 13F filings for Q1 2024.